Human Genome Sciences' two big drugs could make up for years of losses.
Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
We look at how a biotech ETF holds up in an iffy climate for those stocks.
Equity valuations as a whole have barely budged in 2005, but the market remains a bit on the pricey side when comparing to Morningstar's collective fair value estimates (To see more on Morningstar's perspective on market valuations, check out our Market Valuation Graph ). The median stock in our ...